BH.IMMUN&BIO | ERIS LIFESCIENCES | BH.IMMUN&BIO/ ERIS LIFESCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -5.9 | 51.1 | - | View Chart |
P/BV | x | 1.2 | 7.3 | 15.9% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
BH.IMMUN&BIO ERIS LIFESCIENCES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ERIS LIFESCIENCES Mar-24 |
BH.IMMUN&BIO/ ERIS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 971 | 5.3% | |
Low | Rs | 21 | 565 | 3.6% | |
Sales per share (Unadj.) | Rs | 10.3 | 147.7 | 7.0% | |
Earnings per share (Unadj.) | Rs | -3.9 | 29.2 | -13.2% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 42.6 | -8.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 20.4 | 189.7 | 10.8% | |
Shares outstanding (eoy) | m | 43.18 | 136.03 | 31.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 5.2 | 67.3% | |
Avg P/E ratio | x | -9.4 | 26.3 | -35.7% | |
P/CF ratio (eoy) | x | -9.5 | 18.0 | -52.7% | |
Price / Book Value ratio | x | 1.8 | 4.0 | 43.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,561 | 104,470 | 1.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 4,038 | 3.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 20,091 | 2.2% | |
Other income | Rs m | 11 | 238 | 4.5% | |
Total revenues | Rs m | 457 | 20,330 | 2.2% | |
Gross profit | Rs m | -161 | 6,748 | -2.4% | |
Depreciation | Rs m | 2 | 1,826 | 0.1% | |
Interest | Rs m | 71 | 848 | 8.3% | |
Profit before tax | Rs m | -223 | 4,312 | -5.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 342 | -16.5% | |
Profit after tax | Rs m | -166 | 3,971 | -4.2% | |
Gross profit margin | % | -36.0 | 33.6 | -107.2% | |
Effective tax rate | % | 25.3 | 7.9 | 318.9% | |
Net profit margin | % | -37.3 | 19.8 | -188.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 23,790 | 1.5% | |
Current liabilities | Rs m | 940 | 26,090 | 3.6% | |
Net working cap to sales | % | -130.6 | -11.4 | 1,140.4% | |
Current ratio | x | 0.4 | 0.9 | 41.8% | |
Inventory Days | Days | 85 | 17 | 507.7% | |
Debtors Days | Days | 1,135 | 77 | 1,480.9% | |
Net fixed assets | Rs m | 1,262 | 44,398 | 2.8% | |
Share capital | Rs m | 432 | 136 | 317.4% | |
"Free" reserves | Rs m | 450 | 25,675 | 1.8% | |
Net worth | Rs m | 882 | 25,811 | 3.4% | |
Long term debt | Rs m | 0 | 6,545 | 0.0% | |
Total assets | Rs m | 1,620 | 68,188 | 2.4% | |
Interest coverage | x | -2.2 | 6.1 | -35.4% | |
Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.3 | 93.5% | |
Return on assets | % | -5.9 | 7.1 | -83.7% | |
Return on equity | % | -18.9 | 15.4 | -122.6% | |
Return on capital | % | -17.2 | 15.9 | -108.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0.1 | 12,650.1% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | 23 | 280.9% | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 65 | 23 | 280.9% | |
Net fx | Rs m | -65 | -23 | 280.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 4,860 | 2.2% | |
From Investments | Rs m | 5 | -18,545 | -0.0% | |
From Financial Activity | Rs m | -147 | 13,798 | -1.1% | |
Net Cashflow | Rs m | -34 | 382 | -8.8% |
Indian Promoters | % | 59.3 | 54.9 | 108.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 26.6 | - | |
FIIs | % | 0.0 | 8.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 45.1 | 90.3% | |
Shareholders | 35,313 | 46,346 | 76.2% | ||
Pledged promoter(s) holding | % | 0.0 | 18.5 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | ERIS LIFESCIENCES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 2.43% | 0.75% | 1.23% |
1-Month | -8.41% | 7.84% | -0.24% |
1-Year | -5.63% | 45.26% | 43.62% |
3-Year CAGR | -21.40% | 22.75% | 20.35% |
5-Year CAGR | 24.39% | 27.14% | 26.24% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the ERIS LIFESCIENCES share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of ERIS LIFESCIENCES the stake stands at 54.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of ERIS LIFESCIENCES.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
ERIS LIFESCIENCES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of ERIS LIFESCIENCES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day higher, Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.